Pharmaceutical

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 

Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.

Oct 22, 2024 - 04:00
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis 
Arcutis Canada, has received Health Canada's approval for ZORYVE to treat seborrheic dermatitis in patients aged nine years and above.
Read the original article

Tags:

Previous Article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Next Article

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

These are the need-to-know biotech stories from this weekend

These are the need-to-know biotech stories from this we...

Nov 13, 2023

AC Immune wins FDA fast track for Alzheimer’s vaccine candidate

AC Immune wins FDA fast track for Alzheimer’s vaccine c...

Jul 26, 2024

Empress Therapeutics emerges with $50m to fund small molecule development

Empress Therapeutics emerges with $50m to fund small mo...

Jun 21, 2023